DexCom Q3 Results, Higher Revenue Guidance Point to Stronger 2027, RBC Says
Published . Updated .
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
This report does not map to a usual set of affected companies.
Directly affected
- DXCM Dexcom-6.0% 30d
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that DexCom belongs to, so it often moves with news about it.
- SYK Stryker+16.7% 30d
Stryker is a peer of DexCom in surgical and medical instruments and apparatus; rivals often move on the same news.
- MMM 3M+15.1% 30d
3M is a peer of DexCom in surgical and medical instruments and apparatus; rivals often move on the same news.
- BSX Boston Scientific+3.8% 30d
Boston Scientific is a peer of DexCom in surgical and medical instruments and apparatus; rivals often move on the same news.
- BDX Becton, Dickinson and+19.7% 30d
Becton, Dickinson and is a peer of DexCom in surgical and medical instruments and apparatus; rivals often move on the same news.
- MDLN Medline+9.3% 30d
Medline is a peer of DexCom in surgical and medical instruments and apparatus; rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| DXCM | -2.44% | -1.63% | base | +3.04% | +6.10% | +3.87% | +10.76% |
| XLV | -2.61% | -2.65% | base | +0.46% | +0.32% | -0.02% | +3.05% |
| SYK | -1.40% | -3.24% | base | -6.45% | -1.45% | -0.34% | +9.08% |
| MMM | -2.20% | -3.23% | base | -1.73% | +0.57% | -0.18% | +9.39% |
| BSX | +6.99% | +5.61% | base | -1.66% | +3.87% | +1.92% | +7.33% |
| BDX | +0.28% | -1.67% | base | -0.26% | +0.13% | -0.06% | +5.40% |
| MDLN | +6.56% | +1.23% | base | +0.34% | +5.16% | +6.63% | +26.24% |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
DexCom Q3 Results, Higher Revenue Guidance Point to Stronger 2027, RBC Says Yahoo Finance
Source: Yahoo Finance
This story
| Company | When | Move | Status |
|---|---|---|---|
| BDX | that day | -0.26% | final price |
| BDX | the next day | +0.13% | final price |
| BDX | two days later | -0.06% | final price |
| BDX | three days later | +5.40% | final price |
| BDX | three days earlier | -1.67% | final price |
| BDX | five days earlier | +0.28% | final price |
| BSX | that day | -1.66% | final price |
| BSX | the next day | +3.87% | final price |
| BSX | two days later | +1.92% | final price |
| BSX | three days later | +7.33% | final price |
| BSX | three days earlier | +5.61% | final price |
| BSX | five days earlier | +6.99% | final price |
| DXCM | that day | +3.04% | final price |
| DXCM | the next day | +6.10% | final price |
| DXCM | two days later | +3.87% | final price |
| DXCM | three days later | +10.76% | final price |
| DXCM | three days earlier | -1.63% | final price |
| DXCM | five days earlier | -2.44% | final price |
| MDLN | that day | +0.34% | final price |
| MDLN | the next day | +5.16% | final price |
| MDLN | two days later | +6.63% | final price |
| MDLN | three days later | +26.24% | final price |
| MDLN | three days earlier | +1.23% | final price |
| MDLN | five days earlier | +6.56% | final price |
| MMM | that day | -1.73% | final price |
| MMM | the next day | +0.57% | final price |
| MMM | two days later | -0.18% | final price |
| MMM | three days later | +9.39% | final price |
| MMM | three days earlier | -3.23% | final price |
| MMM | five days earlier | -2.20% | final price |
| SYK | that day | -6.45% | final price |
| SYK | the next day | -1.45% | final price |
| SYK | two days later | -0.34% | final price |
| SYK | three days later | +9.08% | final price |
| SYK | three days earlier | -3.24% | final price |
| SYK | five days earlier | -1.40% | final price |
| XLV | that day | +0.46% | final price |
| XLV | the next day | +0.32% | final price |
| XLV | two days later | -0.02% | final price |
| XLV | three days later | +3.05% | final price |
| XLV | three days earlier | -2.65% | final price |
| XLV | five days earlier | -2.61% | final price |
Congressional trades in the stocks in this story
- Rep. Thomas H. Kean Jr sold Stryker (SYK), worth $1,001 - $15,000 on 30 Sep 2026. That is 30 days before publication. Filed 30 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Stryker (SYK) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 35 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Stryker (SYK) (held by a dependent child), worth $15,001 - $50,000 on 11 Sep 2026. That is 49 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Kevin Hern sold Boston Scientific (BSX) (jointly held), worth $50,001 - $100,000 on 9 Sep 2026. That is 51 days before publication. Filed 25 Sep 2026. View the filing.
- Rep. Kevin Hern sold Boston Scientific (BSX) (jointly held), worth $50,001 - $100,000 on 4 Sep 2026. That is 56 days before publication. Filed 25 Sep 2026. View the filing.
- Rep. Kevin Hern sold Boston Scientific (BSX) (held by a dependent child), worth $1,001 - $15,000 on 3 Sep 2026. That is 57 days before publication. Filed 25 Sep 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
This story
12 out of 100
“DexCom Q3 Results, Higher Revenue Guidance Point to Stronger 2027, RBC Says” scores 12 out of 100. The score uses 1 sources.